Fifth, KDM4A is also found to mediate drug resistance to several clinical chemical agents, and abrogating its demethylase activity will restore or sensitize cells to the anticancer activity of chemical drugs, suggesting that single administration or combined therapy using KDM4A inhibitors and chemical agents is a feasible strategy to treat drug-resistant cancers. The gene discussed is MBD2; the disease is cancer.